Cancer vaccine with minimal side effects nearing Phase 3 clinical trials
A personalized cancer vaccine is heading into Phase 3 trials after a remarkable Phase 2 result: nearly 95% of advanced melanoma patients who received only the vaccine were still alive three years later. What makes Dr. Thomas Wagner’s TLPO vaccine so striking isn’t just the survival numbers — it’s the gentleness. Patients report little more than a sore arm and mild fatigue, a world away from the dread of chemotherapy. The vaccine is made from each patient’s own tumor cells, teaching their immune system to recognize cancer as the threat it is. If the larger trial holds up, it could reshape how we think about treating cancer everywhere — not as something to endure, but something to outsmart.









